Coronary flow reserve is associated to adverse events regardless angiographic severity.

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET scan (positron emission tomography). The extension and severity of heart disease was assessed by angiography, and coronary flow reserve (CFR) was measured non-invasively by PET.

After adjusting risk factors, ejection fraction, revascularization, etc, both the severity of angiographic disease and flow reserve by PET were independently associated to these events. 

A significant interaction was observed (p=0.039) between coronary flow reserve and early myocardial revascularization, and low CFR patients who underwent surgery (not PCI) presented events comparable to those of patients with conserved CRF. 

Conclusion

Coronary flow reserve measured with PET was associated to events regardless angiographic severity and this effect was modified with early revascularization. Diffuse arteriosclerosis and microvascular dysfunction could contribute to the physiopathology of cardiovascular mortality and cardiac failure.

7_viviany_taqueti_articulo
Viviany Taqueti
2014-11-17

Original title: Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization.

More articles by this author

Improved survival after out-of-hospital cardiac arrest with the use of automated external defibrillators

This study included patients presenting out of hospital cardiac arrest between 2006 and 2012 in The Netherlands to assess the impact of automated external...

ITALIC PLUS: 6 months of double antiaggregation for no less than 24 months

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy...

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post...

ISAR-SAFE: 6 vs. 12 month clopidogrel administration after DES implantation

The aim of this randomized double blind control trial was to validate the safety and efficacy of 6 months vs. 12 months clopidogrel treatment...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....